Using our innovative technology platform, Viaskin™, we are committed to developing a pipeline of food allergy product candidates that could potentially transform the care of food-allergic patients.
Thank you to all of the patients, caregivers, collaborating physicians and research staff who have enabled our clinical trial development and helped us to advance the potential of Viaskin.
DBV has designed a robust clinical development program that includes investigation of Viaskin™ Peanut (DBV712) and Viaskin™ Milk (DBV135).
Peanut allergy is one of the most common food allergies and can cause severe, potentially fatal, allergic reactions, as well as anaphylaxis.
We have a comprehensive clinical research program in place for Viaskin Peanut. One Phase 3 long-term study in children ages four to 11 is ongoing, as well as two Phase 3 trials in patients ages one to three.
Cow’s Milk Protein Allergy (CMPA) mainly appears in the first year of life and affects approximately 2-3 percent of the population in developed countries.
We completed a Phase 1/2 trial to study the safety and efficacy of Viaskin Milk in pediatric and adolescent patients.
Hen’s egg allergy is one of the most common food allergies in children. Several global studies suggest that egg allergy affects 1.5–3 percent of young children.
The third food allergy to be investigated for treatment with Viaskin is hen’s egg allergy. Pre-clinical work has been initiated for Viaskin Egg.
Investigations Beyond Food Allergies
DBV is investigating other areas of significant unmet medical need, including eosinophilic esophagitis (EoE), inflammatory conditions and autoimmune diseases, as well as the potential application of Viaskin technology to vaccines.
As we focus on diversifying our pipeline, we are also exploring the use of our technology platform in the development of diagnostic tools for food allergies. In 2016, DBV entered an exclusive global collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use and standardized atopy patch test tool for the potential diagnosis of cow’s milk protein allergy in infants and toddlers.